We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Patient Enrollment Resumed in the Investigator-initiated Phase 1/2 Clinical Trial of Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Company Implemented Significant...
Company implementing a series of cost-savings measures designed to extend Salariusβ expected cash runway into the first half of 2025 Extended runway supports the generation of additional data...
Expands IP portfolio with composition-of-matter protection into 2039 for novel molecular glues Protein degrader portfolio now includes 17 issued patents across six patent families HOUSTON, Jan...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0059 | -1.20481927711 | 0.4897 | 0.499 | 0.4632 | 15622 | 0.47505765 | CS |
4 | 0.0138 | 2.93617021277 | 0.47 | 0.5432 | 0.4511 | 29500 | 0.49289234 | CS |
12 | -0.1762 | -26.696969697 | 0.66 | 0.748 | 0.43 | 117494 | 0.52747337 | CS |
26 | -0.1729 | -26.3286127608 | 0.6567 | 0.909 | 0.43 | 72442 | 0.54874293 | CS |
52 | -1.0162 | -67.7466666667 | 1.5 | 1.8694 | 0.43 | 64230 | 0.73387405 | CS |
156 | -32.0162 | -98.5113846154 | 32.5 | 37.25 | 0.43 | 480014 | 16.21902697 | CS |
260 | -288.2662 | -99.8324502165 | 288.75 | 370.385 | 0.43 | 563207 | 28.61193224 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions